
Latest News
Health Canada Approves of DENOZA™, a Denosumab Biosimilar
May 5, 2026
Apotex Inc., a Canadian based global pharmaceutical company announced that Health Canada has approved DENOZA™ (denosumab injection), a denosumab biosimilar, for its authorized indications.
These include the treatment of postmenopausal women with osteoporosis at high risk for fracture and the treatment of osteoporosis in men at high risk for fracture. DENOZA is also authorized for the remaining indications of the reference biologic.
To read the full announcement visit https://www.apotex.com/global/news/news-release/2026/04/07/apotex-strengthens-osteoporosis-care-in-canada-with-health-canada-s-approval-of-denoza-a-denosumab-biosimilar
OC MAKES THE NEWS – RECENT ITEMS
DENOZA® is now available in Canada
Latest News DENOZA® (denosumab injection), a biosimilar from Apotex, is now available in Canada September 25, 2026 PrDENOZA® is indicated for the treatment of postmenopausal osteoporosis, and to increase bone […]
Healthcare Professional Educational Events
Healthcare Professional Educational Events August 19, 2026 View the following information for two events for the healthcare professional: Canadian Symposia on Rare Bone Diseases 2026 ISCD Quality Bone Densitometry: for […]
Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones
Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]
